Xiaojun Guo

机构：Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Fudan University, Zhongshan Hospital, Centre d’Immunologie de Marseille-Luminy · ORCID：0000-0003-0139-3486

发表论文 136 篇 · 总被引 4494 次 · h-index 33

代表论文

• Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study (2024 · The Lancet Haematology · 被引 29)
• Autologous platelet rich plasma injection can be effective in the management of osteoarthritis of the knee: impact on IL-1 β, TNF-α, hs-CRP (2024 · Journal of Orthopaedic Surgery and Research · 被引 12)
• First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• Lysine‐specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti‐programmed death 1 therapy in liver cancer (2025 · Clinical and Translational Medicine · 被引 8)
• Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study (2025 · The Lancet Haematology · 被引 8)
• Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study (2025 · BMC Medicine · 被引 7)